Evidence map›Paper›PMID 24810052›Full record

ArticleCell death & disease2014

Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells.

S Boridy, P U Le, K Petrecca, D Maysinger

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
15.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 79 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. SoloxoloneFrontiers in pharmacology · 2024
    Article
  9. Recent Trends in anti-tumor mechanisms and molecular targets of celastrol.International journal of biological sciences · 2024
    Review
  10. Withaferin A and Celastrol Overwhelm Proteostasis.International journal of molecular sciences · 2023
    Review
  11. Review
  12. Autophagy in the pharmacological activities of celastrol (Review).Experimental and therapeutic medicine · 2023
    Review
  13. Review
  14. Article
  15. Regulation of autophagy as a therapeutic option in glioblastoma.Apoptosis : an international journal on programmed cell death · 2021
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

S BoridyDepartment of Pharmacology and Therapeutics, Faculty of Medicine, McGill University, McIntyre Medical Building, Montreal, Quebec, Canada.ORCID 0000000310876770
P U LeDepartment of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada.
K PetreccaDepartment of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada.
D MaysingerDepartment of Pharmacology and Therapeutics, Faculty of Medicine, McGill University, McIntyre Medical Building, Montreal, Quebec, Canada.
McGill University · CAMontreal Neurological Institute and Hospital · CA

Funding

Canadian Institutes of Health Research MOP-119425Canadian Institutes of Health Research MOP-142626
6 · The paper itself

Abstract

Glioblastoma multiforme is a devastating disease of the central nervous system and, at present, no effective therapeutic interventions have been identified. Celastrol, a natural occurring triterpene, exhibits potent anti-tumor activity against gliomas in xenograft mouse models. In this study, we describe the cell death mechanism employed by celastrol and identify secondary targets for effective combination therapy against glioblastoma cell survival. In contrast to the previously proposed reactive oxygen species (ROS)-dependent mechanism, cell death in human glioblastoma cells is shown here to be mediated by alternate signal transduction pathways involving, but not fully dependent on, poly(ADP-ribose) polymerase-1 and caspase-3. Our studies indicate that celastrol promotes proteotoxic stress, supported by two feedback mechanisms: (i) impairment of protein quality control as revealed by accumulation of polyubiquitinated aggregates and the canonical autophagy substrate, p62, and (ii) the induction of heat-shock proteins, HSP72 and HSP90. The Michael adduct of celastrol and N-acetylcysteine, 6-N-acetylcysteinyldihydrocelastrol, had no effect on p62, nor on HSP72 expression, confirming a thiol-dependent mechanism. Restriction of protein folding stress with cycloheximide was protective, while combination with autophagy inhibitors did not sensitize cells to celastrol-mediated cytotoxicity. Collectively, these findings imply that celastrol targets proteostasis by disrupting sulfyhydryl homeostasis, independently of ROS, in human glioblastoma cells. This study further emphasizes that targeting proteotoxic stress responses by inhibiting HSP90 with 17-N-Allylamino-17-demethoxygeldanamycin sensitizes human glioblastoma to celastrol treatment, thereby serving as a novel synergism to overcome drug resistance.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAutophagyBenzoquinonesBrain NeoplasmsCell Line, TumorDose-Response Relationship, DrugDrug SynergismGlioblastomaHomeostasisHSP90 Heat-Shock ProteinsHumansLactams, MacrocyclicLysosomesPentacyclic TriterpenesProteasome Endopeptidase ComplexProtein Processing, Post-TranslationalBenzoquinonescelastrolHSP90 Heat-Shock ProteinsLactams, MacrocyclicPentacyclic TriterpenesProteasome Endopeptidase ComplexSulfhydryl CompoundstanespimycinTriterpenes

Identifiers

PMID24810052
PMCPMC4047902
OpenAlexW2060278507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.